New data reveal a cancer risk associated with Skysona, a gene therapy for cerebral adrenoleukodystrophy (CALD), with seven cases of blood malignancies reported among 67 treated boys. While the therapy shows promise, concerns about its safety persist, prompting careful consideration by physicians and families. Bluebird bio, the therapy's developer, emphasizes patient well-being and informed decision-making amid ongoing scrutiny.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
